Neurology® Podcast

This month's Delayed Recall highlights episodes on CRISPR gene editing technologies. From February 2017, we have an introduction to CRISPR. Then, there's a 2-part interview with Dr. Kevin Esvelt from February 20 and 27, 2018, on gene drives.

In the first segment, Dr. Stacey Clardy talks with Dr. Richard Burt about his paper on autologous, nonmyeloablative hematopoietic stem-cell transplantation for neuromyelitis optica. In the second part of the podcast, Dr. Stacey Clardy speaks with Dr. Lawrence Weschler about his book on Oliver Sacks, And How are You, Dr. Sacks?, in the first of a two-part interview. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

In the first segment, Dr. Jeff Burns talks with Dr. Randall Bateman about his paper addressing how high precision plasma amyloid-β 42/40 predicts current and future brain amyloidosis. In the second part of the podcast, you'll hear the second part of an interview with Nobel Prize winner Dr. Stanley H. Prusiner. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

In the first segment, Dr. Jeffrey Ratliff talks with Dr. Ylva Hiorth and about their paper on a 7-year prospective population-based study on orthostatic hypotension in Parkinson disease. In the second part of the podcast, Dr. Jason Crowell talks with Nobel Prize winner Dr. Stanley B. Prusiner in the first part of a two-part interview. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

In the first segment, Dr. Greg Day talks with Dr. Kiran Thakur and Dr. Greer Waldrop about their paper on diagnostics for neurologic disorders on the World Health Organization's essential diagnostic list. In the second part of the podcast, Dr. Stacey Clardy speaks with Dr. Sean Pittock on his NEJM paper on eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

This month's Delayed Recall highlights episodes on drug pricing controversies. Dr. Jason Crowell and Professor Robin Feldman start the show discussing "evergreening" and drug prices, which first aired on August 20th, 2019. The next segments, from September 17th and 24th, has Dr. Gordon Smith and Dr. Steve Pearson discussing updates to drug pricing in a follow-up to their earlier talk on the subject. Following this segment is one from May 27th and finds Dr. Jason Crowell talking with Dr. Brian Callaghan about rising out-of-pocket costs for commonly prescribed neurologic medications. This episode concludes with an interview on with Dr. Jason Crowell and Politico reporters Sarah Karlin-Smith and Sarah Owermohle.

In the first segment, Dr. Jason Crowell talks with Dr. Emma Ciafaloni about her clinical/scientific note on combination therapy with nusinersen and AVXS-101 in SMA type 1. In the second part of the podcast, Dr. Jason Crowell speaks with Dr. Douglas Smith on neuroimaging findings in US government personnel with possible exposure to directional phenomena in Havana, Cuba. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

In the first segment, Dr. Stacey Clardy talks with Dr. Mauricio Farez about his practice guideline update summary on vaccine-preventable infections and immunization in multiple sclerosis. In the second part of the podcast, Dr. Gordon Smith continues his discussion with Dr. Steve Pearson on an update on drug pricing. Their previous discussion on drug pricing was featured in two parts on January 8th and January 15th, 2019. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

In the first segment, Dr. Stacey Clardy talks with Dr. Julie Silver about her paper on understanding and addressing gender equity for women in neurology. In the second part of the podcast, Dr. Gordon Smith focuses his discussion with Dr. Steve Pearson on an update on drug pricing. Their previous discussion on drug pricing was featured in two parts on January 8th and January 15th, 2019. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

In the first segment, Dr. Noah Kolb talks with Dr. Amanda Guidon about her paper on varied phenotypes and management of immune checkpoint inhibitor associated neuropathies. In the second part of the podcast, Dr. Stacey Clardy focuses her discussion with Dr. Mike R. Wilson on clinical metagenomic sequencing for diagnosis of meningitis and encephalitis. Read the full NEJM article here: https://www.nejm.org/doi/full/10.1056/NEJMoa1803396. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

This month's Delayed Recall highlights interviews with some of the plenary session speakers from this year's AAN Annual Meeting. We highlight talks with Dr. Jonathan Mink, Dr. Claudia Lucchinetti, Dr. Jed Hartings, Dr. Ronald Melki, and Dr. J. Paul Taylor.

In the first segment, Dr. Alex Menze talks with Dr. Jonathan Newmark about his Neurology: Clinical Practice paper that provides an update on therapy for acute nerve agent poisoning. In the second part of the podcast, Dr. Andrew Schomer focuses his discussion with Dr. Jan Claassen on detection of brain activation in unresponsive patients with acute brain injury. Read the full NEJM article here: https://www.nejm.org/doi/full/10.1056/NEJMoa1812757. Information on managing nerve agent attack can be found here: https://ccc.apgea.army.mil/. Disclosures can be found at Neurology.org. No CME this week: Interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program.

Dr. Stacey Clardy focuses her discussion with Dr. Amanda Grennell on an update on Zika for 2019. Read the full article here: https://www.nature.com/articles/d41586-019-01906-z.

In the first segment, Dr. Stacey Clardy talks with Dr. Anastasia Zekeridou about her paper on Phosphodiesterase 10A-IgG, a novel biomarker of paraneoplastic neurological autoimmunity. In the second part of the podcast, Dr. Jason Crowell focuses his discussion with Prof. Robin Feldman on "evergreening" and drug prices. Read the full article here: https://www.nature.com/articles/d41586-019-01906-z. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

In the first segment, Dr. Jason Crowell talks with Dr. Michele Hu and Dr. David Okai about their longitudinal study of the severity of impulse control disorders in Parkinson disease and RBD. In the second part of the podcast, Dr. Jason Crowell focuses his discussion with Dr. Heidi Ledford on her Nature article discussing CRISPR babies and what would be required to make gene editing safe and acceptable. Read the full article here: https://www.nature.com/articles/d41586-019-01906-z. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

In the first segment, Dr. Stacey Clardy talks with Dr. Robert Zivadinov about cumulative gadodiamide administration leading to brain gadolinium deposition in early MS. In the second part of the podcast, Dr. Jeffrey Ratliff focuses his discussion with Dr. Michael D. Fox on his Brain paper on network localization of cervical dystonia based on causal brain lesions. You can read the paper here: https://academic.oup.com/brain/article-abstract/142/6/1660/5491101?redirectedFrom=fulltext.

This month's Delayed Recall highlights more interviews from our new podcast offering, Neurology Minute. In 2019, Neurology launched a new podcast perfect for Alexa and other similar devices. This episode features digestible "minutes" from June and July. See the instructions for enabling the Neurology Minute on Amazon Alexa below:

In the first segment, Dr. Kristen Heinan talks with Dr. Barbara Weissman about her Neurology: Clinical Practice paper on recommendations for neurologists on the CDC's Guideline on Pediatric Mild Traumatic Brain Injury. In the second part of the podcast, Dr. Will Rondeau focuses his discussion with Dr. Geoffrey Donnan on his NEJM paper on thrombolysis guided by perfusion Imaging up to 9 hours after onset of stroke. You can read the paper here: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1813046.

In the first segment, Dr. Gregory Day talks with Dr. Philip Insel about his paper on determining clinically meaningful decline in preclinical Alzheimer disease. In the second part of the podcast, Dr. Sarah Tabrizi talks about targeting Huntington expression in patients with Huntington's disease in her interview with Dr. Jeffrey Ratliff. Read Dr. Tabrizi's paper in NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa1900907?query=recirc_curatedRelated_article.

In the first segment, Dr. Halley Alexander talks with Dr. Orrin Devinsky about his paper on the full spectrum of epilepsies and the North American SUDEP Registry. In the second part of the podcast, Dr. Ted Burns focuses his discussion with Dr. Gil Wolfe on his Lancet Neurology paper on the long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis. You can read the paper here: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30392-2/fulltext.

In the first segment, Dr. Jeffrey Ratliff talks with Dr. Franziska Hopfner about her paper on the use of ß2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. In the second part of the podcast, Dr. Jason Crowell focuses his discussion with Dr. Jerzy Szaflarski on his JAMA Neurology paper on the US Food and Drug Administration's authorization of the first cannabis-derived pharmaceutical. You can read the paper here: https://jamanetwork.com/journals/jamaneurology/article-abstract/2714720.

In the first segment, Dr. Michelle Mauermann talks with Dr. Bart Jacobs about his paper on current treatment practice of Guillain-Barré syndrome. In the second part of the podcast, Dr. Matthew Harms focuses his discussion with Dr. Guy Rouleau on his Neurology: Genetics paper looking at how somatic expansion of the C9orf72 Hexanucleotide Repeat does not occur in ALS spinal cord tissues.

This month's Delayed Recall highlights interviews on epilepsy and EEG. Dr. Derek Bauer talks with Dr. Paula Emanuela Voinescu about her paper on antiepileptic drug clearances during pregnancy and the relationship between drug serum concentration and seizure frequency from the Sept 25, 2018, podcast. Next, Dr. Andy Schomer talks with Dr. Chloe Hill on the association between continuous EEG and favorable hospitalization outcomes for critically ill patients from the January 1, 2019, podcast. For the next segment, we're back with Derek Bauer, this time talking with Dr. Jacqueline French about the recent practice guideline on the treatment of new-onset epilepsy from the July 10, 2018 episode. And then again from the April 2, 2019, podcast, we hear Derek Bauer talk with Dr. Stephan Schuele about his paper on automated seizure detection accuracy for ambulatory EEG recordings. Finally, we wrap up with Jeff Ratliff talking to Dr. Anup Patel about the 2017 epilepsy quality measurement set update, which originally aired on the October 30, 2018, podcast.

In the second part of a 2-part interview, Dr. Bob Gross discusses changes to the journal and publishing as well as some controversies and challenges as Editor-in-Chief of Neurology.

In the first part of a 2-part interview, Dr. Bob Gross discusses his experiences, opportunities, and challenges as Editor-in-Chief of Neurology.

Dr. Stacey Clardy talks with Dr. P. James B. Dyck about his paper on the incidence of lumbrosacral radiculoplexus neuropathy and association with diabetes mellitus.

Dr. Jason Crowell focuses his talk with Dr. Deborah Dowell on her NEJM perspective article looking at opioid prescribing and response to the CDC guidelines. You can read Dr. Dowell's paper here: https://www.nejm.org/doi/full/10.1056/NEJMp1904190.

This month's Delayed Recall highlights interviews from our new podcast offering, Neurology Minute. In 2019, Neurology launched a new podcast perfect for Alexa and other similar devices. This episode features digestible "minutes" on measles in 2019, gene editing, the SHINE stroke trial, and more.

In the first segment, Dr. Jason Crowell talks with Dr. Brian Callaghan about rising out-of-pocket costs for commonly prescribed neurologic medications. In the second part of the podcast, Dr. Jeffrey Ratliff focuses his interview with Dr. Stefan Pulst on ataxias. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

In the first segment, Dr. Stacey Clardy talks with Dr. Annie Lannuzel about the importance of biological diagnosis in long-term outcome in neuroZika. In the second part of the podcast, Dr. Will Rondeau focuses his interview with Dr. Stuart Connolly on his NEJM paper on the full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. The paper can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa1814051. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

This month's Delayed Recall highlights episodes on developments and scandals related to genetic testing and technology in neurology. Dr. Jason Crowell and Dr. Josephine Johnston of the Hastings Center start the show discussing the ethical and philosophical implications of gene editing., which first aired on December 18th, 2018. The next segment, also from December 18th, has Dr. Stacey Clardy and Dr. Stefan Pulst focusing on the scientific and societal impact of the recent first reported gene editing using the CRISPR technology. Following this segment is one from December 3rd and finds Dr. Jeff Waugh talking with Dr. Saadet Andrews about her paper on the genetic landscape of pediatric movement disorders and management implications. This episode continues with an interview on a Neurology: Genetics on the long journey to diagnosis for patients with mitochondrial disease between Dr. Jason Crowell and Drs. John L.P. Thompson and Michio Hirano from April 3rd, 2018. The episode wraps up with a talk between Dr. Jeffrey Ratliff and Dr. Thomas Bird from March 20th, 2018, on Dr. Bird's Neurology: Clinical Practice paper on the benefits and limitations of exome sequencing to identify hereditary ataxias.

In the first segment, Dr. Lindsay Higdon talks with Dr. Ivan Sanchez Fernandez about his paper on the meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus. In the second part of the podcast, Dr. Stacey Clardy talks with Dr. Anthony Fauci about the measles outbreak of 2019. You can read the paper in NEJM: https://www.nejm.org/doi/full/10.1056/NEJMp1905099.

In the first segment, Dr. Jeffrey Ratliff talks with Dr. Tamara Milka Pringsheim about her practice guideline recommendations summary paper on the treatment of tics in people with Tourette syndrome and chronic tic disorders. In the What's Trending segment, you'll hear the second part of an interview between Dr. Jason Crowell and New York Times staff writer Pam Belluck on CRISPR and gene editing.

In the first segment, Dr. Stacey Clardy talks with Dr. Jenny Linnoila about her March 2019 Neurology: Neuroimmunology & Neuroinflammation paper on a mouse model of anti-NMDA receptor post–herpes simplex encephalitis. In the second segment, Jason Crowell talks with Pam Belluck of the New York Times about He Jiankui, gene editing, and CRISPR.

In the first segment, Dr. Gregory Day talks with Dr. Brigid Waldron-Perrine about her Neurology: Clinical Practice paper addressing the Montreal Cognitive Assessment as a screening tool. In the second part of the podcast, Dr. Jeffrey Burns focuses his interview with Dr. Mathias Jucker on how serum neurofilament dynamics predict neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. The article can be found in Nature: https://www.nature.com/articles/s41591-018-0304-3.

In the first segment, Dr. Stacey Clardy talks with Dr. Mathias Buron about his paper addressing the comparative effectiveness of teriflunomide and dimethyl fumarate. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Joanna Hellmuth on the rise of pseudomedicine for dementia and brain health.

In the first segment, Dr. Stacey Clardy talks with Dr. Caterina Lapucci about her paper addressing how much periventricular lesions assist in distinguishing migraine with aura from CIS. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Sarah Karlin-Smith and Sarah Owermohle from Politico on drug pricing.

In the first segment, Dr. Derek Bauer talks with Dr. Stephan Schuele about his paper on automated seizure detection accuracy for ambulatory EEG recordings. In the second part of the podcast, Dr. Nicole Chiota-McCollum focuses her interview with Dr. Kevin Barrett on the SHINE stroke trial.

Dr. Luca Bartolini discusses autoimmune encephalitis and the role of antibody testing based on a Practice Current survey run between November 2017 and May 2018.

Dr. Jeffrey Ratliff talks with Dr. Anneleen Berende about her paper on the effect of prolonged antibiotic treatment on cognitive performance in patients with Lyme borreliosis. Dr. Andrew Southerland focuses his interview with Dr. Stephen Klasko on hospitals of the future, following a panel at the World Economic Forum in Davos, Switzerland. The article can be found here: https://www.statnews.com/2019/01/26/dispatch-from-davos-future-hospitals/.

This month's Delayed Recall highlights episodes on autoimmune neurology. A segment from October 23, 2018 finds Dr. Stacey Clardy talking to Dr. Andrew McKeon about his paper on paraneoplastic neuronal intermediate filament autoimmunity. This episode concludes with an interview on a Neurology: Neuroimmunology & Neuroinflammation paper on IgLON5 autoimmunity between Dr. Stacey Clardy and Dr. Andrew McKeon from March 27, 2018.

In the first segment, Dr. James Grogan talks with Dr. David Llewellyn about his Neurology: Clinical Practice paper on predictors of dementia misclassification when using brief cognitive assessments. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Rob M.A. de Bie on a randomized delayed-start trial of Levodopa in Parkinson's Disease, published in the New England Journal of Medicine. The article can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa1809983.

1. A multicentre comparison of MOG-IgG cell based assays. 2. [What's Trending]: the DEFUSE 3 study. In the first segment, Dr. Stacey Clardy talks with Dr. Paddy Waters about his paper on a multicentre comparison of MOG-IgG cell based assays. In the second part of the podcast, Dr. Andrew Southerland focuses his interview with Dr. Adam de Havenon on the DEFUSE 3 study. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

1. The prevalence of MS in the United States: A population-based estimate using health claims data. 2. [What's Trending]: Neurology on the Hill and advocacy issue. In the first segment, Dr. Stacey Clardy talks with Dr. Mitch Wallin about his paper examining a population-based estimate on the prevalence of MS in the United States. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Nick Johnson on Neurology on the Hill and advocacy issues. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

1. Quality Improvement in Neurology: Universal Neurology Quality Measurement Set Executive Summary2. [What's Trending]: The 2018 report of the Lancet Countdown on health and climate change: shaping the health of nations for centuries to come. In the first segment, Dr. Stacey Clardy talks with Dr. Wayne Anderson and Dr. Justin Martello about their paper on quality improvement in neurology. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Nick Watts on health and climate change shaping the health of nations for centuries to come. DISCLOSURES: Dr. Stacey Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Wayne Anderson reports no disclosures. Dr. Justin Martello has received travel funding or speaker honoraria from 1) Teva, cash, (2) Abbvie, cash, (3) Lundbeck, cash and is a member of the AAN's Quality and Safety Subcommittee. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

1.Physical activity, common brain pathologies, and cognition in community-dwelling older adults 2. [What's Trending]: Deep space medicine. In the first segment, Dr. Jeff Burns talks with Dr. Aron Buchman about his paper on physical activity, common brain pathologies, and cognition in community-dwelling older adults. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Alejandro Rabinstein on the medicine of deep space. Dr. Jeff Burns has served on the DSMB for three NIH-funded trials; has received honorarium and travel for speaking at an Astra-Zeneca symposium; has served on the editorial board of Journal of Alzheimer's Disease; has served as a consultant for protocol development for Stage 2 Innovations; has received commercial research support from Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, vTv Therapeutics, Janssen, and Roche and for investigator-initiated studies from Eli Lilly and Astra-Zeneca; has received governmental research support from the National Institutes of Health; and has provided expert witness testimony in legal cases. Dr. Aron Buchman has received government research support from the National Institutes of Health. Dr. Jason Crowell reports no disclosures. Dr. Alejandro Rabinstein has served as a member of the external committee for adverse event adjudication for PREVAIL trial/CAP2 registry; has served on the editorial boards of Neurology, Neurocritical Care, Stroke, CONTINUUM , and UpToDate; and has received publishing royalties from Elsevier and Oxford.

1.Quality of Life Outcomes in Patients Presenting for Evaluation of Central Nervous System Tumors 2. [What's Trending]: 'Landmark study' shows brain cells revamp their DNA, perhaps sparking Alzheimer's disease. In the first segment, Dr. Ted Burns talks with Dr. Irene Katzan about her paper on quality of life outcomes in patients presenting for evaluation of central nervous system tumors. In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Jerold Chun on a 'Landmark study' showing brain cells revamp their DNA, perhaps sparking Alzheimer's disease.Dr. Ted Burns has served on scientific advisory boards for Argenx, Momenta, received travel funding or speaker honoraria from Argenx, Alexion and received support for consulting activities from UCB Pharma, CSL Behring, Momenta, Argenx. Dr. Irene Katzan has served on editorial boards for Stroke (American Stroke Association), 2014-present Editorial Board - Circulation: Cardiovascular Quality & Outcomes (American Heart Association) 2013 – present. Dr. Irene Katzan has received research from one commercial entity including Novartis Pharmaceuticals and received research support from the following government entity: Ohio Department of Health - Physician Lead for the Ohio Paul Coverdell Stroke Registry, 2007-2020. Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001).Dr. Jerold Chun reports no disclosures.

1. Reducing neurodisparity: Recommendations of the 2017 AAN Diversity Leadership Program 2. [What's Trending]: Mapping Symptoms to Brain Networks with the Human Connectome. In the first segment, Dr. Teshamae Monteith talks with Dr. Roy Hamilton about his paper on reducing neurodisparity. In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Michael D. Fox on mapping symptoms to brain networks with the human connectome.DISCLOSURES Dr. Teshamae Monteith has served on Scientific Advisory Boards for Lilly, Supernus, Teva, Electrocore, Promius and is an editorial advisory board member for Neurology. Dr. Roy Hamilton has served without compensation on the scientific advisory board for an NIH-funded R21 project titled ""Combining tDCS and neurorehabilitation to treat age-related deficits of mobility and cognition (UPfront Walking Study) as the data safety monitor. Dr. Hamilton has served on editorial boards for (1)Cognitive and Behavioral Neurology, editorial board member, and (2)Restorative Neurology and Neuroscience, editorial board member, 2011 to present. Dr. Hamilton is employed by Neuronix LTD as a Medical consultant, 2014 to present. Dr. Hamilton has done consultancies for Geurbet Ltd. on the development of an FDA-mandated clinical trial and received approximately $6000 for work in the last 2 years (2017-18). Dr. Hamilton received research support from 1) NIH/NIA 5P30-AG-010124-27 Co-Investigator 7/15/97-6/30/19 2) NIH/NIDCD 1 R01 DC012780-01A1 Principal Investigator 7/01/2013 - 6/30/2019 3) NIH/NIDCD 2-R01-DC-009209-11 Co-Investigator 6/01/2014 - 5/31/2019 4) NIH/NIDCR DP5OD021352 Co-Investigator 9/19/2015 - 08/31/2020 5) NIH/NIDCD 1R01DC015359-01A1 Co-Investigator 4/01/2016 - 3/31/2021 6) University of Pennsylvania/Translational Neuroscience Initiative (TNI) Co-Investigator 7/01/2016 - 6/30/2019 . 7) NIH/NEI R01EY022350 Co-Investigator 9/01/2016 - 8/31/2021 8) NIH/NINDS 5P30NS045839-12 Co-Investigator 2/1/2014-1/31/2018 9) Templeton Foundation/Imagination Institute Principal Investigator 7/01/2015 – 6/30/2017 10) Association for Frontotemporal Dementia Principal Investigator 1/01/2016 – 12/31/2016 11) Dana Foundation Principal Investigator 12/13/2012 - 4/24/2018. Dr. Hamilton's legal proceedings include Kline & Specter Attorneys at Law, Consultant, 2014, 2015. Dr. Stacey Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Michael D. Fox has patents issues or submitted using brain imaging to guide brain stimulation. Dr. Fox has done consultancies for Mint Labs and has received research support from one government entity (1) NIH, K23NS083741 and research support from two foundations and societies (1) Dystonia Medical Research Foundation (2) National Parkinson's Foundation.

1. Brain death, the determination of brain death, and member guidance for brain death accommodation requests: AAN position statement. 2. [What's Trending]: On tau protein and Alzheimer dementia symptoms. In the first segment, Dr. Jason Crowell talks with Dr. James Russell about his paper on brain death, the determination of brain death, and member guidance for brain death accommodation requests. In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Matthew Brier on tau protein and Alzheimer dementia symptoms.DISCLOSURES: Dr. Jason Crowell reports no disclosures. Dr. James Russell has served on Scientific Advisory Boards for Cytokinetics - Data Monitoring Board PROTOCOL CY 5022 A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, DOSE- RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CK-2127107 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS). Dr. James Russell received travel funding from 1) Non-profit - Mexican Academy of Neurology - Funded travel and lodging to speak at Annual Meeting Nov 2018 - no honorarium (2) Non-profit - ALS Association - funded travel and lodging to do site visit for ALSA certification of UVA ALS Clinic. Dr. James Russell has publishing royalties from (1) Neuromuscular Disorders, McGraw-Hill, 2nd edition published 2015, with subsequent royalities 2) Honorarium for published article in Continuum: Approach to peripheral neuropathy. Continuum: Peripheral Nervous System Disorders. Fall 2017. Dr. James Russell has done consultancies with compensation for market research interviews regarding ALS therapeutics and is currently being compensated for expert opinion in two medical legal cases, one in support of the defendant and one in support of the plaintiff. Dr. Matthew Brier has received funding for Biogen, travel and accommodation and received research support for Medical Scientist Training Program Grant to WUSTL (5T32GM007200-37.

1. Aspirin Reduces Long Term Stroke Risk in Women with Prior Hypertensive Disorders of Pregnancy 2. [What's Trending]: Top-selling drug price hikes and patients bearing the cost. In the first segment, Dr. Andrew Southerland talks with Dr. Eliza Miller about her paper on aspirin reducing the long term stroke risk in women with prior hypertensive disorders of pregnancy. In the second part of the podcast, Dr. Ted Burns focuses his talk with Casey Ross on makers of top-selling drugs hiking prices and patients bearing the costs.DISCLOSURES: Dr. Eliza Miller has served on Editorial Boards for Stroke, Assistant Editor, InterSECT, 2017-2018. Dr. Eliza Miller Research Support, Government Entities including (1) NIH NINDS 5U10NS086728-05, Fellow, 2017-2018 (2) NIH NINDS U01 NS095869, Subsite PI, 2018 (3) NIH NCATS 5KL2TR001874-02, KL2 Scholar, 2018-2020 and she has received research support from Foundations and Societies including American Medical Association Foundation and Louis V. Gerstner Foundation. Casey Ross reports no disclosures.